Navigation Links
Consortium finds chronic liver cirrhosis clues
Date:3/13/2011

Researchers have provided new clues into the genetics underlying a chronic form of liver disease, called primary biliary cirrhosis, which can lead to transplant surgery for patients. The new study identifies 15 genetic regions that affect a person's risk of developing the disease, more than trebling the number of known genetic regions, which now stands at 22.

The study was based on the genomes of 2,500 patients with primary biliary cirrhosis and more than 7,500 apparently healthy people. The results are the first to emerge from the Wellcome Trust Case Control Consortium 3 (WTCCC3) project, a collaboration of UK scientists and clinicians, which aims to unravel the role of genetic variation in several human diseases. The findings suggest that several key immune processes underlie susceptibility to primary biliary cirrhosis (PBC).

Patients with primary biliary cirrhosis suffer irritation and swelling of the bile ducts of the liver blocking the flow of bile, which normally aids digestion. The obstruction damages liver cells and leads to scarring, known as cirrhosis. Primary biliary cirrhosis is thought to affect approximately 35 out of every 100,000 adults, but that rate almost trebles to 95 out of 100,000 in women over the age of 45. As there are no proven treatments available, the majority of patients will require a liver transplant.

The specific biological pathways underlying primary biliary cirrhosis are poorly understood although autoimmunity, where the body attacks its own cells, is known to play a significant role.

"To gain an insight into the causes of primary biliary cirrhosis we compared genetic data from patients and healthy volunteers and found 22 regions of the genome that differed significantly, 15 of which had not previously been identified," says Dr Carl Anderson, from the Wellcome Trust Sanger Institute and one of the senior authors on the paper. "By scrutinizing the genes within these regions we were able to identify biological pathways that appear to underpin the disease, thus prioritising these for future research and highlighting their potential for therapeutic intervention."

"This study is a key first step in our efforts to unravel the biological complexity of primary biliary cirrhosis and further research building on these results is already underway."

The team found that many of the 15 new regions contain genes involved in regulation of the immune system, with three immune pathways particularly prominent. One of these, called the NF-кB pathway, had not previously been associated with primary biliary cirrhosis although it had been implicated in other autoimmune and inflammatory diseases such as rheumatoid arthritis, multiple sclerosis and asthma. In total, five of the identified genomic regions are thought to play a role in this pathway and further work is being planned to elucidate how genetic mutations in these regions cause primary biliary cirrhosis and other related diseases.

"For clinicians involved in the management of primary biliary cirrhosis, this study is exciting because it provides new and meaningful insight into the biological origins of this condition," says Dr George Mells, from the Academic Department of Medical Genetics at the University of Cambridge and a first author on the study. "This will undoubtedly inform the development of more effective treatments, designed to target the biological pathways involved in causing the disease. The study is also a triumph of collaboration. Every NHS Trust in the UK was involved in recruitment of patients and the patient community itself was mobilised by efforts from the PBC Foundation.

"By working together, we have recruited almost one in six primary biliary cirrhosis patients in the UK; completed the largest genome-wide association study of primary biliary cirrhosis to date and established a research consortium that will form the foundation of further clinical, genetic and therapeutic studies".

This research contributes to the growing body of evidence that suggests there are many genetic risk factors that are shared between autoimmune diseases. Of the 22 regions identified in this study of primary biliary cirrhosis, 12 have previously been associated with other autoimmune disorders such as type-1 diabetes, multiple sclerosis and psoriasis. Working out how these shared pathways interact with those that, at this moment in time, appear to be unique to primary biliary cirrhosis is likely to lead to important therapeutic breakthroughs.

"The publication of this paper is no routine academic matter for people with primary biliary cirrhosis," says Collette Thain, MBE, Chief Executive of the PBC Foundation. "For us, it means hope one step towards understanding how best to treat and cure. It is a testament to the perseverance and ingenuity of all the scientists who worked on this project. But because this was a collaborative project, part funded by the PBC Foundation and directly involving patients, it is also an example of how people with conditions like primary biliary cirrhosis can work together with scientists and physicians to find solutions.

"As a sufferer myself, it is hard to put into words what an exciting breakthrough like this means to me and all the other people with primary biliary cirrhosis. Research like this brings a brighter tomorrow ever closer."


'/>"/>

Contact: Don Powell
press.office@sanger.ac.uk
44-012-234-96928
Wellcome Trust Sanger Institute
Source:Eurekalert

Related biology news :

1. Research consortium to sequence turkey genome
2. NIH Clinical and Translational Science Consortium grows to 39 members
3. International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury
4. SRI announces selection by the National Cancer Institute as a Chemical Biology Consortium center
5. NIDCR launches the FaceBase Consortium
6. Duke and the International Serious Adverse Event Consortium to partner on research
7. Duke and the Internationalserious Adverse Event Consortium to partner on research
8. $15 million stimulus award creates national consortium for revealing scientific resources
9. University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium
10. Biomedical research infrastructure goes global: EU consortium Infrafrontier has new partners
11. WHOI joins consortium to study, minimize effects of Gulf Oil spill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... They call it the ... network, a depiction of a system of linkages and connections so complex and ... professor of computer science at Worcester Polytechnic Institute (WPI) and director of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer ... that they have entered into a multiyear collaboration to identify and characterize novel ... additional tools for gene editing across all applications. , Under the terms of ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage ... its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats ... sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
Breaking Biology Technology: